Why a 2.50x Risk of Dementia Is Worse Than You Think

saxsa Eriksen

- 

In late-stage colonialism, we’ve forgotten that two-thirds of the world’s population doesn’t live, eat, or medicate like the West. So why do we keep calling data “global” when it only applies to a narrow, industrialized demographic?

I recently discovered — with the help of common sense — that scientific studies often focus more on statistical significance than actual patient experience. This raises a serious question about the credibility of modern Western medicine.

Take a dementia risk increase of 2.50x — specifically tied to medications like gabapentin. Sounds alarming, right?
Well, it’s often dismissed as “not clinically significant.” Why?
Because when averaged over the entire global population, the percentage looks small.

But that’s the lie.

Because the people affected — the ones showing measurable cognitive decline, suicide ideation, and neuroinflammatory symptoms — aren’t “average.”


They’re:

  • Middle-class individuals from industrialized countries

  • Often eating ultra-processed, high-sugar diets due to poverty or convenience

  • Prescribed pharmaceuticals developed in Western labs, not adapted to whole-body resilience

  • Living under chronic stress, sedation, and artificial stimulus

And when you give this group a drug that floods sensitive calcium channels in the brain — and potentially causes long-term PV+ interneuron damage — it’s not “only 1.5%.”

It’s a controlled demolition of memory, executive function, and emotional regulation.

Risks in the cronnicly ill populus is also watered down the same way.

Patents risks are being calculated with ⅔ of people not using or having access to the same treatments - this is medical neglegence.  

If a patient is not aware of individual risk, it cannot consent eticly.

persional experience - Pattern Recognition - Clinical Obfuscation via Patient History

Subject:
Documented pattern of harm deflected through psychiatric profiling.

Statement:
Pharmaceutical intervention was initiated without full disclosure of long-term neurological risk, particularly in relation to gabapentinoids and antipsychotics with known anticholinergic burden. Upon iatrogenic destabilization, the patient's response was reinterpreted not as pharmacological injury, but as a recurrence of pre-existing psychiatric history.

This history—documented prior to the prescription—was subsequently used as a narrative shield to deflect responsibility and suspend critical inquiry into treatment-induced harm.

At no point was the following considered:

  • The dose-response relationship of withdrawal symptoms

  • The established role of calcium dysregulation in PV interneuron collapse

  • The failure to follow established taper protocols (e.g., Ashton-style or equivalent GABAergic withdrawal guidance)

Instead, adverse effects were reclassified as behavioral pathology, with diagnostic inflation used as a retrospective justification for the intervention itself.

Conclusion:
Patient history was not used to prevent harm.
It was used to frame the aftermath of harm.
This constitutes a recursive pattern of psychiatric laundering: the transformation of pharmacological injury into psychiatric identity.



Tilbake til bloggen

Legg igjen en kommentar